Pharmaceuticals

Eli Lilly's Zepbound secures a landmark approval for sleep apnea, moving beyond weight loss to redefine chronic disease management and challenge competitors.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

LRM Aesthetics' new delivery system for its PDGF+ formula isn't just a product update; it’s a masterclass in how small innovations create major workflow gains.

A biotech firm's non-hallucinogenic drug just passed a key safety test. Could this novel approach finally disrupt the challenging world of alcohol use disorder?

A new patent gives Cognition Therapeutics’ lead drug candidate protection until 2045. Here’s why this strategic move is about more than just IP.

Acumen Pharmaceuticals unveils two new candidates using a novel technology to deliver therapies directly to the brain, promising a more effective fight against AD.

A new pact between Canada’s CASTL and Ireland’s NIBRT, backed by top leaders, aims to solve a critical talent shortage and secure the global pharma supply chain.

The 8th annual 'Shine the Light' campaign unites 47 groups to fight Sickle Cell Disease, but behind the red-lit landmarks lies a deeper crisis of access to new, multi-million dollar cures.

Pharma giant MSD and health-tech innovator Nivi are using an AI chatbot to fight cervical cancer in Asia. Can this model overcome regulatory hurdles and scale?

Biotech firm ProJenX reports its novel ALS drug, prosetin, is safe and hits key targets in early trials, offering a new beacon of hope for the disease.

Pasithea Therapeutics is expanding its NF1 trial for PAS-004, a move that signals a deeper strategic commitment to outmaneuvering competitors and meeting a critical unmet medical need.

The appointment of drug development veteran Dr. Aaron Koenig at Syremis Therapeutics is more than a new hire; it's a strategic play in the high-stakes race to redefine mental health treatment.

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

A new survey reveals an overwhelming public demand to treat epinephrine like defibrillators. This isn't just about allergies; it's a systemic shift in our definition of public safety.

Acurx Pharma's new drug, ibezapolstat, offers a novel weapon against deadly infections like C. diff by sparing good bacteria. Is this the breakthrough we need?

Tiny biotech HCW Biologics reports promising early data for its alopecia drug. But with a small sample size and big pharma rivals, is this a true breakthrough?

As USANA marks 10 years of its World Service Week, a closer look reveals how its direct-selling network is strategically engineered to power a global charity.

Edgewise Therapeutics unveils strong Phase 2 data for its HCM drug, EDG-7500, showing efficacy without the cardiac risks plaguing market leaders.

A short-seller report alleges ADMA faked 20% growth, triggering a 40% stock collapse and a securities fraud lawsuit with an August 10 investor deadline.

With a major debt financing, French biotech Inventiva is funded through a pivotal Phase 3 trial for its MASH drug, highlighting a strategic shift in biotech funding.